'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains

Albuterol Generic Builds Big Rx Share In US Proventil Market

The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.

Red umbrella protecting merchants immune novel coronavirus pneumonia infection
Some Gains from COVID-19 Portfolio May Be Sustainable • Source: Shutterstock

An endemic coronavirus appears to be the premise that leading Indian firm Cipla Limited is factoring into its business, at least for now, and that in turn could mean a sustained revenue stream for its COVID-19 therapies in the immediate future.

Cipla saw strong growth of its prescription business in India in the second quarter of fiscal 2021, driven by continued...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip